Business context and reporting period
This is Trxade Group, Inc.’s unaudited Form 10-Q for the three months ended March 31, 2015. The company operates a pharmaceutical business-to-business marketplace, pharmaceutical supply business, and IT consulting subsidiary. The request metadata names Scienture Holdings, Inc.; that does not match the registrant identified in this filing and should be verified.
Financial results and liquidity
| Metric | Q1 2015 | Q1 2014 / comparison |
|---|---|---|
| Revenue | $696,133 | $244,196; up approximately 185% |
| Gross profit / margin | $465,670 / 66.9% | $97,406 / 39.9% |
| Operating loss | $(442,651) | $(344,517) |
| Net loss | $(443,620) | $(921,995) |
| Loss per share | $(0.01), basic and diluted | $(0.03), basic and diluted |
| Operating cash flow | $(370,304) | $(249,358) |
| Cash | $335,298 at March 31, 2015 | $705,602 at December 31, 2014 |
| Working capital | $338,256 | $664,639 at December 31, 2014 |
Total assets were $952,463 and current liabilities were $611,605 at March 31, 2015. No separate long-term debt balance is presented. The company reported no financing cash flows in Q1 2015. Cash declined by $370,304 during the quarter. Operating cash use exceeded the prior-year quarter by $120,946.
Material changes and management commentary
- Management attributed higher revenue mainly to platform fee income and customer growth through direct marketing and training. Increased pharmaceutical sales also raised cost of sales.
- General and administrative expense was $908,321 in the financial statements, including $116,037 of stock-option expense. Management attributed higher expenses principally to increased staffing and reported payroll expense of $443,444.
- The prior-year quarter included a $576,417 loss on debt conversion; its absence was a major reason the net loss narrowed despite a larger operating loss.
- Inventory increased to $150,964 from $46,429 at year-end; accounts payable rose to $375,784 from $291,059.
Outlook, contingencies and unusual items
- Management estimated the next 12 months’ cost of sales and general and administrative expenses at $750,000 and $2,050,000, respectively, or $2.8 million in total. It said additional funding would be needed to expand the platform, grow the customer base, and cover operating needs; financing availability and terms are not assured.
- Subsequent to quarter-end, the company issued $200,000 of one-year convertible promissory notes in April and May 2015. Interest is payable at maturity; the stated conversion price is $1.50 per share. Holders received 50,000 warrants with a $1.50 strike and five-year expiration. The filing does not clearly state the interest rate.
- The company granted 480,000 employee options during the quarter and forfeited 320,000 unvested options. It reported $309,108 of unrecognized option compensation cost expected to be recognized over 4–5 years.
- Management concluded disclosure controls and procedures were not effective. No material change in internal control over financial reporting was reported for the quarter. The filing reports no legal proceedings.
- Management cautioned that interim results are not necessarily indicative of full-year results and that forward-looking statements are subject to risks and uncertainty.
Important facts for investors to verify
- Confirm the issuer identity: the supplied metadata says Scienture Holdings, Inc., while the filing is for Trxade Group, Inc.
- Review the filing’s apparent inconsistencies: the balance-sheet heading refers to March 31, 2014 although the presented column is March 31, 2015; MD&A reports December 31 current liabilities as $553,667 versus $553,677 on the balance sheet; and the EPS note gives a 2014 basic-loss numerator of $(951,995), inconsistent with the reported net loss of $(921,995).
- Assess the company’s funding needs against its $335,298 quarter-end cash balance, $370,304 quarterly operating cash use, and estimated $2.8 million next-12-month expenses.
- Review the terms and dilution implications of the subsequent $200,000 convertible notes and warrants, and the substantial stock-option awards and related compensation expense.